A new publications characterizes the distinctive in vitro agonist properties of NLX-112, a potential drug therapy for L-DOPA-induced dyskinesia (LID) in Parkinson's disease. NLX-112 was tested in a variety of in vitro assays of serotonin 5-HT1A receptor activation and consistently exhibited very high agonist efficacy. NLX-112 also exhibited preferential activation of a specific G-protein subtype (Go), unlike other compounds such as NLX-101, which is being developed by Neurolixis for Rett syndrome. Overall, the study provides further pharmacological support for the superior profile of NLX-112 compared to previous serotonergic agonists.

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist

Newman-Tancredi A, Martel J-C, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.
Journal of Pharmacy and Pharmacology, 2017 June 14. DOI: 10.1111/jphp.12762



Veuillez activer le javascript sur cette page pour pouvoir valider le formulaire

Follow Neurolixis on: